FyMed, Inc.

Press Releases
2015

FyMed Expands Its Discovery and Drug Development Plans Through Innovative Strategies in Precision Medicine

FyMed, Inc. today announced strategic and operational expansion plans following the successful completion of major preclinical drug studies utilizing innovative companion diagnostic and prognostic technologies in precision medicine.
Read More...

FyMed Announces Notice of Allowance for US Patent Covering Fy10 Technology Platform

FyMed Inc., a specialty pharmaceutical company focused on the development and commercialization of novel therapeutics announced that its application covering the Fy10 technology platform was allowed for issuance as a new patent by the USPTO. Read More...

Early Release: FyMed Gets Patent for Novel Immunomodulatory Drug

Pharmaceutical firm FyMed Inc. has received a patent for a novel immunomodulatory drug used in the treatment of autoimmune diseases.
Read More...

FyMed Heralds Breakthrough in the Treatment of Colon Cancer with Novel Drug Candidate FY405B

Scientists at FyMed, Inc. have identified a novel drug target in the management of colon cancer, developing a candidate that has shown significant promise for the treatment of this difficult-to-treat disease in early studies. Read More...